The next-generation compound, NNZ-2591, is planned to be taken all the way through to Phase 3 trials in-house, with hopes of completing all four proposed trials within the next three years. While the cost of trials could run between US$50 million and US$100 million each (depending on patient numbers), if successful, NEU aspires to almost 'double' the royalty and milestone metrics it achieved for the US licensing of DAYBUE, where Acadia had funded the Phase 3 trials.
An interesting view on what “is planned” to happen next.
- Forums
- ASX - By Stock
- Neuren Media and Analyst Coverage
The next-generation compound, NNZ-2591, is planned to be taken...
-
- There are more pages in this discussion • 81 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
|
|||||
Last
$21.27 |
Change
0.650(3.15%) |
Mkt cap ! $2.718B |
Open | High | Low | Value | Volume |
$20.84 | $21.56 | $20.76 | $7.760M | 364.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 1378 | $21.24 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$21.29 | 218 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 200 | 21.240 |
1 | 47 | 21.150 |
1 | 500 | 20.860 |
1 | 240 | 20.800 |
1 | 50 | 20.630 |
Price($) | Vol. | No. |
---|---|---|
21.300 | 12763 | 1 |
21.350 | 30 | 1 |
21.380 | 471 | 1 |
21.410 | 25 | 1 |
21.500 | 60 | 1 |
Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online